Role of HIV on Glutathione Synthesis and Oxidative Stress
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Houston |
| State: |
|
Texas |
| Zip Code: |
|
77030 |
| Conditions: |
|
HIV Infection - Erythrocyte Glutathione Deficiency |
| Purpose: |
|
HIV infection is associated the development of increased oxidative stress and deficiency of
glutathione (GSH), the dominant endogenous antioxidant protein, but the underlying
mechanisms contributing to GSH deficiency are hitherto unknown. Furthermore GSH metabolism
has not been studied in HIV patients, in whom the burden of risk factors promoting oxidative
stress is highest. Our previous studies in non-HIV human subjects with diabetes-related
oxidative stress and GSH deficiency have demonstrated that the latter is due to decreased
synthesis of GSH. Importantly, short-term dietary supplementation with the simple GSH
precursor amino-acids cysteine and glycine, boosted GSH synthesis and cellular
concentrations, corrected GSH deficiency, and reduced oxidative stress and oxidant damage.
The current proposal will study whether (1) defective synthesis underlies GSH deficiency in
patients with HIV, and will test a simple, inexpensive and rational therapy based on protein
supplementation to improve GSH synthesis and concentrations and lower markers of oxidative
stress and oxidant damage in these patients; (2) study if correction of GSH deficiency is
asssociated with any changes in (a) impaired mitochondrial fuel oxidation in the fasted and
insulin stimulated states; (b) insulin sensitivity; (c) body composition and anthropometry;
(d) forearm muscle strength; (e) plasma biochemistry, and (f) quality of life indices in
these subjects.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
(1) HIV infected patients with GSH deficiency
Exclusion Criteria:
1. renal impairment (serum Creatinine above 1.5mg/dL), liver impairment (ALT and AST >
2x upper limit of normal)
2. any hormonal disorders such as hypothyroidism, hypercortisolemia, hypogonadism, or
diabetes mellitus on pharmacotherapy
3. evidence of infections other than HIV in the preceding 3 months
4. subjects with plasma triglyceride concentrations of ≥ 500mg/dL on triglyceride
lowering therapy
5. BMI < 20
6. established heart disease
7. Co-existing viral hepatitis B and C
|
| NCT ID: |
|
NCT01355198 |
| Primary Contact: |
|
Principal Investigator
R V Sekhar, MD
Baylor College of Medicine
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Houston, Texas 77030
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|